The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4639-4647

  Ohta, Tsuyoshi ^a   Isobe, Masanori ^a   Takahashi, Toshifumi ^a   Saitoh Sekiguchi, Maki ^a   Motoyama, Teiichi ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Akt; Chemotherapy; ERK; Ovarian cancer; Prognosis

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; PROTEIN KINASE B;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 75149175604     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Berkenblit A and Cannistra SA: Advances in the management of epithelial ovarian cancer. J Reprod Med 50: 426-438, 2005.
2. Pfisterer J and Ledermann JA: Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 33: S12-16, 2006.
3. Blackledge G, Lawton F, Redman C and Kelly K: Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59: 650-653, 1989.
4. Aoki K, Ogawa T, Ito Y and Nakashima S: Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep 11: 375-379, 2004.
5. Benhar M, Engelberg D and Levitzki A: Cisplatin-induced activation of the EGF receptor. Oncogene 21: 8723-8731, 2002.
6. Villalonga P, Guasch RM, Riento K and Ridley AJ: RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol 24: 7829-7840, 2004.
7. Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511, 1998.
8. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995.
9. Pap M and Cooper GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932, 1998.
10. Yao R and Cooper GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267: 2003-2006, 1995.
11. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G and Testa JR: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280-285, 1995.
12. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267-9271, 1992.
13. Davidson B, Espina V, Steinberg SM, Florenes VA, Liotta LA, Kristensen GB, Trope CG, Berner A and Kohn EC: Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 12: 791-799, 2006.
14. Egan SE and Weinberg RA: The pathway to signal achievement. Nature 365: 781-783, 1993.
15. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
16. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60: 5988-5994, 2000.
17. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D and Murata Y: Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274: 31648-31654, 1999.
18. Ohta T, Ohmichi M, Hayasaka T, Mabuchi S, Saitoh M, Kawagoe J, Takahashi K, Igarashi H, Du B, Doshida M, Mirei IG, Motoyama T, Tasaka K and Kurachi H: Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147: 1761-1769, 2006.
19. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K and Murata Y: Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277: 33490-33500, 2002.
20. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998.
21. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
22. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M and Inoue M: Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 98: 652-658, 2007.
23. Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC and Landberg G: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24: 4370-4379, 2005.
24. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Trope CG and Reich R: Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91: 160-172, 2003.
25. Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke FE and Fenic I: Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch 450: 387-395, 2007.
26. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS and Muschel RJ: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885-892, 2002.
27. Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI and Hidalgo M: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9: 2478-2486, 2003.
28. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
29. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932-22940, 1999.
30. Duriez PJ and Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75: 337-349, 1997.
31. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M and Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100: 281-287, 2002.
32. Sui M, Xiong X, Kraft AS and Fan W: Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther 5: 1015-1021, 2006.
33. Cartee L, Kucera GL and Willingham MC: Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin. Apoptosis 3: 439-449, 1998.
34. Wang J, Zhou JY and Wu GS: ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67: 11933-11941, 2007.
35. Hu L, Zaloudek C, Mills GB, Gray J and Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294O02). Clin Cancer Res 6: 880-886, 2000.
36. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V and Loning T: Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92: 2206-2215, 2005.
37. Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, Hashimoto M, Takakura M and Inoue M: Concomitant activation of AKT with extracellular- regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss. Cancer Sci 98: 1881-1888, 2007.
38. Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, Swinson DE, Patel D, Jones JL and O'Byrne KJ: Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 11: 2930-2936, 2005.
39. Kodama Y, Baxter RC and Martin JL: Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line. Am J Respir Cell Mol Biol 27: 336-344, 2002.
40. Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res 69: 1748-1757, 2009.
41. Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D and Fang B: Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK. Oncogene 23: 4984-4992, 2004.
42. WAF1/CIP1, Bcl-2 and Bcl-xL expression. Gynecol Oncol 105: 373-384, 2007.
43. waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate. Cancer Gene Ther 15: 576-590, 2008.